Antiangiogenic concentrations of vinflunine increase the interphase microtubule dynamics and decrease the motility of endothelial cells.
Angiogenesis is a key event in tumor progression and metastasis. This complex process, which constitutes a potent target for cancer therapy, is inhibited by very low concentrations of microtubule-targeting drugs (MTD). However, the intimate mechanisms of the antiangiogenic activity of MTDs remain unclear. Recently, we have shown that low antiangiogenic and noncytotoxic concentrations of paclitaxel induced an unexpected increase in microtubule dynamics in endothelial cells. In this study, we showed that vinflunine, the newest Vinca alkaloid, increased microtubule dynamic instability in human endothelial cells after 4-hour incubation at low concentrations (29% and 54% at 0.1 and 2 nmol/L). The growth and shortening rates were increased, and the percentage of time spent in pause and the mean duration of pauses were decreased, as previously observed with paclitaxel. As opposed to paclitaxel, the transition frequencies were not significantly disturbed by vinflunine. Moreover, low concentrations of vinflunine did not affect mitotic index and anaphase/metaphase ratio. Interestingly, these low vinflunine concentrations that increased microtubule dynamics exhibited an antiangiogenic effect through the inhibition of both morphogenesis and random motility. Capillary tube formation on Matrigel was decreased up to 44%. The cell speed and the random motility coefficient were decreased (13% and 19% and 13% and 33% at 0.1 and 2 nmol/L, respectively) and the persistent time was statistically increased. Altogether, our results confirm that the increase in microtubule dynamics is involved in MTD antiangiogenic activity and highlight the crucial role of interphase microtubule dynamics in angiogenesis.
Pourroy
Bertrand
B
Centre National de la Recherche Scientifique-FRE 2737, CISMET, Université de la Méditerranée, Marseilles, France.
Honoré
Stéphane
S
Pasquier
Eddy
E
Bourgarel-Rey
Véronique
V
Kruczynski
Anna
A
Briand
Claudette
C
Braguer
Diane
D
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D002196:Capillaries / Q000187:drug effects / Q000254:growth & development; D048708:Cell Growth Processes / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects*; D003094:Collagen; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D042783:Endothelial Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D007399:Interphase / Q000187:drug effects / Q000502:physiology; D007797:Laminin; D008870:Microtubules / Q000187:drug effects* / Q000502:physiology; D008938:Mitosis / Q000187:drug effects; D011509:Proteoglycans; D014747:Vinblastine / Q000031:analogs & derivatives* / Q000494:pharmacology
D020533:Angiogenesis Inhibitors; D004338:Drug Combinations; D007797:Laminin; D011509:Proteoglycans; C059485:matrigel; C111217:vinflunine; D014747:Vinblastine; D003094:Collagen